Shin Dong-bin: “Biotech Is Lotte’s Future Growth Engine” ... CDMO Bet in Songdo
- Input
- 2026-11-18 15:14:46
- Updated
- 2026-11-18 15:14:46

Lotte Group Chairman Shin Dong-bin reaffirmed his commitment to fostering the bio business, making the remarks at the completion ceremony for the first plant at Lotte Biologics’ Songdo Bio Campus held on the 18th.
A new business set to lead Lotte Group’s future beyond retail and chemicals has taken its first concrete steps in Songdo. Lotte, which entered the contract development and manufacturing organization (CDMO) business for biopharmaceuticals in 2022, has laid the groundwork for expanding the business by acquiring U.S. production facilities and securing a large-scale production base in South Korea.
In his congratulatory remarks, Chairman Shin said, “I hope the first plant at the Songdo Bio Campus will be an important turning point that raises the competitiveness of South Korea’s bio industry to a new level, beyond contributing to Lotte Group’s growth.” He added, “We will create quality jobs and develop specialized bio talent centered in Songdo, while working with the government, relevant organizations, clients and partners to contribute to the development of South Korea’s bio industry and strengthen national competitiveness.”
In fact, Chairman Shin has personally overseen key business sites as he works to make bio a future growth engine for the group. After attending the groundbreaking ceremony for the first Songdo plant in July 2024, he visited the plant for the first time this July to review its production facilities and the status of orders from global clients. At the time, he also identified bio as a key industry that would drive the group’s next leap forward and urged that thorough preparations be made for commercial production.
Construction of the first Songdo plant began in March 2024. The facility has a capacity of 120,000 liters and is equipped with eight stainless-steel bioreactors, each with a capacity of 15,000 liters. Its total floor area is approximately 99,558 square meters, and it received approval for use in June. Preparations for production under Good Manufacturing Practice (GMP) standards were completed six months ahead of schedule, and procedures for commercial production, including equipment qualification assessment and validation, are now underway. Full-scale commercial production is targeted for 2027.
Lotte Biologics CEO Shin Yoo-yeol said, “The completion of the Songdo Bio Campus is significant not only because it marks the completion of a new production facility, but also because it lays the groundwork for Lotte Biologics to help increase large-scale production capacity in South Korea’s bio industry.” He added, “We will be a CDMO partner that works alongside customers for the long term, grounded in quality, technology and trust that customers can experience firsthand.” The occasion was also significant as CEO Shin’s first official engagement since he was promoted to president of Lotte Corporation on the 16th.
[email protected] Jung Sang-hee Reporter